All In Biotech

Drug Trial Radar · NCT03115112

Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

A Phase 3, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effects of Bexagliflozin Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin

Last checked: Nov 20, 2026Latest source record: Jun 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 386 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

386

Actual

Start

Oct 12, 2017

Primary completion

Oct 31, 2018

Study completion Oct 31, 2018

Sponsor

Lead sponsor
TheracosIndustry
Sponsor type
Industry
First posted
Apr 14, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the effect of bexagliflozin compared to sitagliptin as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • BexagliflozinDrug

    tablets containing 20 mg bexagliflozin

  • SitagliptinDrug

    tablets containing 100 mg sitagliptin

  • Placebo for sitagliptinDrug

    inactive tablets to match the appearance of sitagliptin tablets

  • Placebo for bexagliflozinDrug

    inactive tablets to match the appearance of bexagliflozin tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c From Baseline to Week 24Time frame: Baseline to week 24

Locations

56 sites in 6 countries. Site status is shown where the registry gives one.

  • Clinical Research Site 1357

    Lincoln, California

  • Clinical Research Site 1358

    Long Beach, California

  • Clinical Research Site 1361

    San Dimas, California

  • Clinical Research Site 1031

    Port Orange, Florida

  • Clinical Research Site 1271

    Chicago, Illinois

  • Clinical Research Site 1359

    Topeka, Kansas

  • Clinical Research Site 1009

    Berlin, New Jersey

  • Clinical Research Site 1037

    Trenton, New Jersey

  • Clinical Research Site 1008

    Munroe Falls, Ohio

  • Clinical Research Site 1360

    San Antonio, Texas

  • Clinical Research Site 3119

    Hodonín, Czechia

  • Clinical Research Site 3123

    Mladá Boleslav, Czechia

  • Clinical Research Site 3120

    Olomouc, Czechia

  • Clinical Research Site 3112

    Prague, Czechia

  • Clinical Research Site 3122

    Prostějov, Czechia

  • Clinical Research Site 9102

    Balatonfüred, Hungary

  • Clinical Research Site 9101

    Balatongyörök, Hungary

  • Clinical Research Site 9106

    Budapest, Hungary

  • Clinical Research Site 9107

    Szeged, Hungary

  • Clinical Research Site 9105

    Zalaegerszeg, Hungary

  • Clinical Research Site 9103

    Zamárdi, Hungary

  • Clinical Research Site 6031

    Chiba, Japan

  • Clinical Research Site 6037

    Chiba, Japan

  • Clinical Research Site 6042

    Chiba, Japan

  • Clinical Research Site 6040

    Fukuoka, Japan

  • Clinical Research Site 6035

    Fukuoka, Japan

  • Clinical Research Site 6034

    Ibaraki, Japan

  • Clinical Research Site 6039

    Ibaraki, Japan

  • Clinical Research Site 6041

    Ibaraki, Japan

  • Clinical Research Site 6032

    Ibaraki, Japan

  • Clinical Research Site 6033

    Ōsaka, Japan

  • Clinical Research Site 6036

    Shizuoka, Japan

  • Clinical Research Site 6038

    Tochigi, Japan

  • Clinical Research Site 7137

    Gdansk, Poland

  • Clinical Research Site 7144

    Krakow, Poland

  • Clinical Research Site 7142

    Krakow, Poland

  • Clinical Research Site 7139

    Krakow, Poland

  • Clinical Research Site 7141

    Krakow, Poland

  • Clinical Research Site 7120

    Lublin, Poland

  • Clinical Research Site 7138

    Lublin, Poland

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.